{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:21:50Z","timestamp":1790778110081,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bulcan.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T18:08:00Z","timestamp":1579630080000},"page":"21-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["VIH et cancer\u00a0: mise au point en 2020"],"prefix":"10.1016","volume":"107","author":[{"given":"Baptiste","family":"Abbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Veyri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Poizot-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2020.01.001_bib0185","series-title":"Global HIV & AIDS statistics \u2014 2019\u00a0fact sheet [Internet]","year":"2019"},{"issue":"8","key":"10.1016\/j.bulcan.2020.01.001_bib0190","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996\u00a0and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.bulcan.2020.01.001_bib0195","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/QAD.0000000000000222","article-title":"Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000","volume":"28","author":"Morlat","year":"2014","journal-title":"Aids"},{"issue":"2","key":"10.1016\/j.bulcan.2020.01.001_bib0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2020.01.001_bib0205","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2\u00a0trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.bulcan.2020.01.001_bib0210","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.bulcan.2020.01.001_bib0215","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.bulcan.2020.01.001_bib0220","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/QAD.0000000000000382","article-title":"Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997\u00a0and 2009: results from a French cohort","volume":"28","author":"Hleyhel","year":"2014","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.bulcan.2020.01.001_bib0225","series-title":"Le VIH\/sida en France en 2018 [Internet]. vih.org","year":"2018"},{"issue":"12","key":"10.1016\/j.bulcan.2020.01.001_bib0230","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1470-2045(09)70282-7","article-title":"Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study","volume":"10","author":"Guiguet","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.01.001_bib0235","series-title":"Retour d\u2019informations clinico\u00e9pid\u00e9miologiques (RICE) [Internet]","author":"Inserm U943","year":"2013"},{"issue":"11","key":"10.1016\/j.bulcan.2020.01.001_bib0240","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Spectrum of cancer risk among HIV-infected people in the United States during the modern antiretroviral therapy era: a population-based registry linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.bulcan.2020.01.001_bib0245","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cid\/ciy012","article-title":"Cancer risk in older persons living with human immunodeficiency virus infection in the United States","volume":"67","author":"Mahale","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.bulcan.2020.01.001_bib0250","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.aids.0000238411.75324.59","article-title":"Trends in cancer risk among people with AIDS in the United States 1980\u20132002","volume":"20","author":"Engels","year":"2006","journal-title":"AIDS Lond Engl"},{"issue":"6","key":"10.1016\/j.bulcan.2020.01.001_bib0255","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/QAD.0000000000000163","article-title":"Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States","volume":"28","author":"Robbins","year":"2014","journal-title":"AIDS Lond Engl"},{"issue":"4","key":"10.1016\/j.bulcan.2020.01.001_bib0260","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cid\/ciw764","article-title":"HIV infection, immunosuppression, and age at diagnosis of non-AIDS-defining cancers","volume":"64","author":"Shiels","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2020.01.001_bib0265","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1086\/375844","article-title":"Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population","volume":"37","author":"Sav\u00e8s","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.bulcan.2020.01.001_bib0270","doi-asserted-by":"crossref","first-page":"e14349","DOI":"10.1371\/journal.pone.0014349","article-title":"HIV tropism and decreased risk of breast cancer","volume":"5","author":"Hessol","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bulcan.2020.01.001_bib0275","series-title":"Groupe d\u2019experts pour la prise en charge du VIH","first-page":"26","author":"Blanc","year":"2017"},{"issue":"9","key":"10.1016\/j.bulcan.2020.01.001_bib0280","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cncy.21571","article-title":"Screening to prevent anal cancer: current thinking and future directions","volume":"123","author":"Palefsky","year":"2015","journal-title":"Cancer Cytopathol"},{"issue":"21","key":"10.1016\/j.bulcan.2020.01.001_bib0285","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1209120","article-title":"Results of initial low-dose computed tomographic screening for lung cancer","volume":"368","author":"National Lung Screening Trial Research Team","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2020.01.001_bib0290","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/1055-9965.EPI-11-0777","article-title":"HIV infection, immunodeficiency, viral replication, and the risk of cancer","volume":"20","author":"Silverberg","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.bulcan.2020.01.001_bib0295","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.autrev.2014.04.005","article-title":"Autoimmune diseases in HIV-infected patients: 52\u00a0cases and literature review","volume":"13","author":"Iordache","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.bulcan.2020.01.001_bib0300","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rmr.2016.03.007","article-title":"[Biological follow-up of patients with HIV treated with anti-PD-1\u00a0or anti-PD-L1\u00a0for non-small cell bronchial carcinoma: a task group proposal]","volume":"33","author":"Guihot","year":"2016","journal-title":"Rev Mal Respir"},{"issue":"2","key":"10.1016\/j.bulcan.2020.01.001_bib0305","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAD.0000000000002397","article-title":"Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?","volume":"34","author":"Abbar","year":"2020","journal-title":"AIDS Lond Engl"},{"issue":"3","key":"10.1016\/j.bulcan.2020.01.001_bib0310","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajco.12838","article-title":"Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis","volume":"14","author":"Man","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2020.01.001_bib0315","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS Lond Engl"},{"issue":"7","key":"10.1016\/j.bulcan.2020.01.001_bib0320","doi-asserted-by":"crossref","first-page":"e1005761","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3\u00a0contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PLoS Pathog"},{"issue":"7588","key":"10.1016\/j.bulcan.2020.01.001_bib0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1\u00a0replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.bulcan.2020.01.001_bib0330","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1097\/QAD.0b013e328340a239","article-title":"Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication","volume":"24","author":"Chun","year":"2010","journal-title":"AIDS Lond Engl"},{"issue":"7408","key":"10.1016\/j.bulcan.2020.01.001_bib0335","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bulcan.2020.01.001_bib0340","doi-asserted-by":"crossref","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1\u00a0latency in vivo","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.bulcan.2020.01.001_bib0345","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1002\/eji.201545513","article-title":"Toward a cure for HIV\u2014Seeking effective therapeutic vaccine strategies","volume":"45","author":"Autran","year":"2015","journal-title":"Eur J Immunol"},{"issue":"7109","key":"10.1016\/j.bulcan.2020.01.001_bib0350","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1\u00a0expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2020.01.001_bib0355","first-page":"10","article-title":"PD-1\u00a0blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals","author":"Fromentin","year":"2019","journal-title":"Nat Commun [Internet]"},{"issue":"2","key":"10.1016\/j.bulcan.2020.01.001_bib0360","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120300035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120300035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:31:31Z","timestamp":1757791891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120300035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0007455120300035"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.01.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VIH et cancer\u00a0: mise au point en 2020","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}